Supported by an educational grant from Novartis Pharmaceuticals Corporation
The signs and symptoms of worsening chronic heart failure (HF) can develop insidiously and are easy to miss, particularly when patients present with atypical features such as cough, loss of appetite, and confusion. The situation is compounded when patients fail to report these nonspecific symptoms because they think they are unrelated to the heart. In this video, an emergency medicine specialist and a cardiologist discuss practical strategies for ongoing monitoring and clinical assessment, including the use of noninvasive cardiac imaging and the role of biomarkers in risk assessment and prognostication.
This activity is designed for cardiologists, internists, and other clinicians who care for patients with chronic heart failure, including primary care physicians (ie, family medicine/general practice), nurse practitioners, and physician assistants.
At the conclusion of this activity, participants should be better able to:
Assess patients’ global clinical status, including prompt recognition of worsening HF
Conflict Of Interest Disclosure Policy
In accordance with the ACCME Standards for Commercial Support, Haymarket Medical Education requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.
Phillip D. Levy, MD, MPH, FACEP, FAHA, FACC Professor and Associate Chair for Research Department of Emergency Medicine Assistant Vice President, Translational Science and Clinical Research Innovation Wayne State University Detroit, MI
Dr. Levy has been a consultant for Apex Innovations, AstraZeneca, Novartis Pharmaceuticals, Ortho Diagnostics, Roche Diagnostics, Sciex, Shire, and Siemens; has served on the speakers’ bureau for Medscape; and has conducted research funded by Amgen, Bristol-Myers Squibb, Edwards Lifesciences, Gilead Sciences, Novartis Pharmaceuticals Corporation, Ortho Diagnostics, and Pfizer Inc. He also has ownership interest in Emergencies in Medicine and in Mespere Life Sciences.
David E. Lanfear, MD, MS Section Head, Advanced Heart Failure and Transplant Cardiology Henry Ford Hospital Professor of Medicine Wayne State University Detroit, MI
Dr. Lanfear has been a consultant for ACI (Clinical Events Committee for ABBOTT trial), Akros (Steering Committee for a clinical trial), Amgen, Duke Clinical Research Institute, and Ortho McNeil (Clinical Events Committee). He has also conducted research funded by Novartis Pharmaceuticals Corporation and Janssen.
Accredited Provider Disclosure
Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.
AMA PRA Category 1 Credit(s)TM
Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Haymarket Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 CreditTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Additional Credit Information
Physician Assistant Continuing Education AAPA accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 0.25 Category 1 Credit for completing this activity.
Nurse Practitioner Continuing Education AANPCP accepts certificates of participation for educational activities approved for AMA PRA Category 1 CreditTM from organizations accredited by ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.
Disclosure of Unlabeled Use
This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient’s medical condition.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Novartis Pharmaceuticals Corporation or Haymarket Medical Education. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
To obtain credit, a score of 100% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.